Paper29907489
Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes.
Holliday EB and 7 others. Int J Radiat Oncol Biol Phys, 2018. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. Papers, record 29907489. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29907489
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anus Neoplasms | Major topic |
| Aorta | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Chemoradiotherapy | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Lymphatic Metastasis | |
| Male | |
| Middle Aged | |
| Retrospective Studies | |
| Safety | |
| Survival Analysis |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938788 | Inguinal or Para-Aortic Lymph Node Metastasis in Colorectal Cancer: A Narrative Review of Different Treatment Approaches. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938788 | PubMed |
| 42583102 | Management of oligometastatic anal cancer-a literature review and a proposed treatment algorithm. | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42583102 | PubMed |
| 36975459 | Anal Cancer: The Past, Present and Future. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36975459 | PubMed |
| 35936677 | Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35936677 | PubMed |
| 35723900 | Radiodermatitis: severity, predictive factors and discontinuation of radiotherapy in patients with anal and rectal cancer. | Rev Esc Enferm USP | 2022 | https://conductscience.org/library/papers/35723900 | PubMed |
| 34946287 | A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus-A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group. | Medicina (Kaunas) | 2021 | https://conductscience.org/library/papers/34946287 | PubMed |
| 34490075 | Effective Organs-at-Risk Dose Sparing in Volumetric Modulated Arc Therapy Using a Half-Beam Technique in Whole Pelvic Irradiation. | Front Oncol | 2021 | https://conductscience.org/library/papers/34490075 | PubMed |
| 32460785 | Patterns of recurrence in anal cancer: a detailed analysis. | Radiat Oncol | 2020 | https://conductscience.org/library/papers/32460785 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29907489
GET https://conductscience.org/api/papers/v1/29907489/authors